3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
5
Breast
2
Head & Neck
1
Gastrointestinal
1
CNS
1
Conditions
Pancreatic Neoplasms
14
Colorectal Neoplasms
13
Rectal Neoplasms
5
Colonic Neoplasms
4
Adenocarcinoma
4
Liver Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Neoplasm Metastasis
2
Melanoma
2
Esophageal Neoplasms
2
Barrett Esophagus
2
Adenocarcinoma Of Esophagus
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Resectable Pancreatic Ductal Adenocarcinoma
1
Prostatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Ovarian Neoplasms
1
Obesity
1
Non-DM Stage II High-risk Colorectal Cancer
1
Neoplasms
1
Motor Activity
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Insulin Resistance
1
Hepatitis C, Chronic
1
Glioma
1
Interventions
pembrolizumab
50
Cyclophosphamide
25
Carboplatin
25
Gemcitabine
20
Cisplatin
19
fludarabine
18
Nivolumab
17
Paclitaxel
16
Bevacizumab
15
Specimen Handling
14
Fluorouracil
11
Magnetic Resonance Spectroscopy
10
aldesleukin
9
Oxaliplatin
9
Irinotecan
9
Docetaxel
9
Biopsy
9
olaparib
8
Trastuzumab
8
durvalumab
7
atezolizumab
7
Hyperthermic Intraperitoneal Chemotherapy
7
Albumin-Bound Paclitaxel
7
Taxes
6
Leucovorin
6
Ipilimumab
6
Interleukin-2
6
Cetuximab
6
Capecitabine
6
130-nm albumin-bound paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Metformin
×
Gastrointestinal
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn